{"hands_on_practices": [{"introduction": "A central skill in experimental immunology is the ability to translate raw data into meaningful biological metrics. This practice challenges you to do just that, using data from flow cytometry—a workhorse technique for analyzing cell populations. By carefully accounting for cells at different stages of antibody isotype switching, you will calculate the operational frequency of Class Switch Recombination (CSR) [@problem_id:2858720], reinforcing your understanding of how this process is quantified in a laboratory setting.", "problem": "A purified population of murine naive B lymphocytes is stimulated in vitro under conditions that induce Class Switch Recombination (CSR) to immunoglobulin G subclass 1 (IgG1). Class Switch Recombination (CSR) is defined as the recombination-driven replacement of the immunoglobulin heavy chain constant region, which changes the isotype (for example, from immunoglobulin M (IgM) to immunoglobulin G subclass 1 (IgG1)) without altering the antigen-binding variable region. Flow cytometry is used to quantify surface immunoglobulin heavy chain isotypes at baseline and after stimulation. Assume the following scientifically standard measurement and biological premises as the foundation for quantification:\n- CSR yields gain of the IgG1 constant region and, upon completion, loss of the IgM constant region on the same heavy chain locus.\n- Flow cytometry detects surface protein; cells undergoing CSR can transiently co-express both isotypes, producing an IgM-positive and IgG1-positive double-positive population.\n- Percentages reported for an isotype gate include any double-positive cells that fall within that gate.\n- The total live B-cell fraction remains stable across the measurement interval, and the emergence of immunoglobulin G subclass 1 (IgG1)-positive cells at the endpoint arises from CSR among the initially immunoglobulin M (IgM)-positive B cells.\n- Baseline immunoglobulin G subclass 1 (IgG1) positivity is negligible.\n\nYou are given the following flow cytometry observations:\n- At baseline, the fraction of immunoglobulin M (IgM)-positive cells is $90\\%$.\n- At $72$ hours, the fraction of immunoglobulin M (IgM)-positive cells is $40\\%$, the fraction of immunoglobulin G subclass 1 (IgG1)-positive cells is $50\\%$, and the immunoglobulin M (IgM)-positive and immunoglobulin G subclass 1 (IgG1)-positive double-positive fraction is $10\\%$.\n\nOperationally define the CSR frequency to immunoglobulin G subclass 1 (IgG1) as the fraction of the initially immunoglobulin M (IgM)-positive cohort that has completed CSR to immunoglobulin G subclass 1 (IgG1) by the $72$-hour time point, where completion is indicated by cells that are immunoglobulin G subclass 1 (IgG1)-positive and immunoglobulin M (IgM)-negative at $72$ hours. Compute this CSR frequency using only the given measurements. Express your final answer as a unitless decimal. Round your answer to three significant figures.", "solution": "The problem requires the computation of the Class Switch Recombination (CSR) frequency to immunoglobulin G subclass 1 (IgG1), based on flow cytometry data from an in vitro B lymphocyte culture. The problem statement has been validated and found to be scientifically sound, consistent, and well-posed. We may proceed with the solution.\n\nLet the total population of live B lymphocytes be normalized to $1$. The fractions given in the problem represent subpopulations relative to this total. We define the following variables based on the provided data:\n\n- $M_0$: The fraction of immunoglobulin M (IgM)-positive cells at the baseline time point ($t=0$). From the problem, $M_0 = 0.90$.\n- $M_{72}$: The fraction of IgM-positive cells at the $72$-hour time point. From the problem, $M_{72} = 0.40$.\n- $G_{72}$: The fraction of IgG1-positive cells at the $72$-hour time point. From the problem, $G_{72} = 0.50$.\n- $(M \\cap G)_{72}$: The fraction of cells that are double-positive for both IgM and IgG1 at the $72$-hour time point. From the problem, $(M \\cap G)_{72} = 0.10$.\n\nThe CSR frequency, which we denote as $F_{CSR}$, is operationally defined as the fraction of the initially IgM-positive cohort that has completed CSR by the $72$-hour time point. Completion of CSR is indicated by cells that are IgG1-positive and IgM-negative.\n\nFirst, we must determine the fraction of the total cell population that has completed CSR. These are the cells that are IgG1-positive but IgM-negative at $t=72$ hours. Let us denote this fraction as $G_{sp}$, where 'sp' signifies 'single-positive' for IgG1. This population is the set of all IgG1-positive cells from which the double-positive (IgM-positive and IgG1-positive) cells have been excluded.\n\nThe total fraction of IgG1-positive cells, $G_{72}$, is the sum of two disjoint populations: the cells that are single-positive for IgG1 ($G_{sp}$) and the cells that are double-positive for both IgG1 and IgM ($(M \\cap G)_{72}$). This can be expressed as:\n$$G_{72} = G_{sp} + (M \\cap G)_{72}$$\nWe can solve for $G_{sp}$, the fraction of cells that have completed CSR:\n$$G_{sp} = G_{72} - (M \\cap G)_{72}$$\nSubstituting the given values:\n$$G_{sp} = 0.50 - 0.10 = 0.40$$\nThus, $40\\%$ of the total live B-cell population consists of cells that have completed CSR to IgG1.\n\nNext, we must construct the fraction for the CSR frequency, $F_{CSR}$. The definition specifies that this frequency is relative to the *initially* IgM-positive cohort. The size of this initial cohort, as a fraction of the total population, is given as $M_0$.\n$$M_0 = 0.90$$\nThe problem states that IgG1-positive cells emerge from the initial IgM-positive population. Therefore, the numerator of our frequency calculation is the fraction of cells that have completed CSR ($G_{sp}$), and the denominator is the fraction of cells that were initially IgM-positive ($M_0$).\n\nThe CSR frequency is therefore calculated as the ratio:\n$$F_{CSR} = \\frac{G_{sp}}{M_0}$$\nSubstituting the calculated and given values:\n$$F_{CSR} = \\frac{0.40}{0.90} = \\frac{4}{9}$$\nTo provide the final answer as a decimal rounded to three significant figures, we perform the division:\n$$F_{CSR} \\approx 0.4444...$$\nRounding to three significant figures, we obtain:\n$$F_{CSR} \\approx 0.444$$\nThis value represents the fraction of the original IgM-bearing B cells that have successfully switched to producing IgG1 and ceased producing IgM by the $72$-hour mark.", "answer": "$$\\boxed{0.444}$$", "id": "2858720"}, {"introduction": "Beyond the population level, a firm grasp of CSR requires understanding its irreversible impact on the genome of a single B cell. The process operates under a simple but strict rule: recombination between two switch regions deletes the intervening DNA. This thought experiment [@problem_id:2858655] tests your ability to apply this fundamental principle rigorously, forcing you to deduce the genetic fate of an intervening constant region gene following a switch to a downstream isotype.", "problem": "B cells undergoing class switch recombination (CSR) at the immunoglobulin heavy-chain (IgH) locus use recombination between switch (S) regions to loop out and delete the intervening constant region DNA, driven by Activation-Induced Cytidine Deaminase (AID). Consider a simplified linear IgH locus segment in which the relevant constant regions appear in the order $S\\mu$–$C\\mu$–$S\\gamma 1$–$C\\gamma 1$–$S\\alpha$–$C\\alpha$, and assume all switch regions are in the same transcriptional orientation so that CSR is deletional. A population of activated B cells is driven to produce immunoglobulin A (IgA) by CSR. In this population, $60$ percent of cells complete IgA switching by a single direct $S\\mu$–$S\\alpha$ join, while $40$ percent complete IgA switching via a two-step pathway that first joins $S\\mu$–$S\\gamma 1$ and then $S\\gamma 1$–$S\\alpha$. Under these conditions, and using only the described mechanistic properties of CSR (that recombination between two S regions deletes the intervening DNA on the chromosome), compute the expected fraction of cells that retain the $C\\gamma 1$ exons on the chromosome after they have completed switching to IgA. Express your answer as a decimal fraction with no units. No rounding is necessary.", "solution": "The problem is subjected to validation and is found to be valid. It is scientifically grounded in the principles of immunology, specifically class switch recombination (CSR), and is well-posed, providing all necessary information for a unique solution.\n\nThe central principle of this problem is the mechanism of deletional class switch recombination at the immunoglobulin heavy-chain (IgH) locus. The problem states that the relevant gene segments are arranged linearly in the order $S\\mu$–$C\\mu$–$S\\gamma 1$–$C\\gamma 1$–$S\\alpha$–$C\\alpha$. It explicitly defines the mechanistic rule: \"recombination between two S regions deletes the intervening DNA on the chromosome.\" The objective is to determine the fraction of a B cell population that retains the $C\\gamma 1$ exons on the chromosome after completing a switch to produce immunoglobulin A (IgA).\n\nWe are given two pathways by which an activated B cell, initially expressing IgM (utilizing the $C\\mu$ gene), can switch to expressing IgA (utilizing the $C\\alpha$ gene). Let us analyze the state of the $C\\gamma 1$ gene for each pathway.\n\nPathway 1: Direct $S\\mu$ to $S\\alpha$ switch.\nThis pathway is followed by a fraction $F_1 = 0.60$ of the cell population. The recombination event occurs between the $S\\mu$ switch region and the $S\\alpha$ switch region. According to the stated rule, the entire DNA segment located between $S\\mu$ and $S\\alpha$ is looped out and deleted from the chromosome. The initial configuration is:\n$$ \\text{... } S\\mu \\text{ – } C\\mu \\text{ – } S\\gamma 1 \\text{ – } C\\gamma 1 \\text{ – } S\\alpha \\text{ ...} $$\nThe segment `– Cμ – Sγ1 – Cγ1 –` lies between $S\\mu$ and $S\\alpha$. Upon recombination, this entire segment is excised. The resulting chromosome will have a hybrid $S\\mu/S\\alpha$ switch region followed by the $C\\alpha$ exons, allowing for IgA production. As the $C\\gamma 1$ gene is part of the deleted segment, it is not retained on the chromosome. For this subpopulation of cells, the fraction retaining $C\\gamma 1$ is $0$.\n\nPathway 2: Sequential $S\\mu \\to S\\gamma 1 \\to S\\alpha$ switch.\nThis pathway is followed by a fraction $F_2 = 0.40$ of the cell population. This process involves two distinct recombination events.\nStep (a): $S\\mu \\to S\\gamma 1$ recombination. In this step, the $S\\mu$ region recombines with the $S\\gamma 1$ region. The intervening DNA, which contains the $C\\mu$ gene, is deleted. The chromosomal configuration becomes:\n$$ \\text{... } S\\mu/S\\gamma 1 \\text{ – } C\\gamma 1 \\text{ – } S\\alpha \\text{ – } C\\alpha \\text{ ...} $$\nAt this intermediate stage, the cell produces IgG1, and the $C\\gamma 1$ gene is retained on the chromosome.\nStep (b): $S\\gamma 1 \\to S\\alpha$ recombination. The problem states that the cell then switches from producing IgG1 to IgA. This requires a second recombination event, this time between the newly formed hybrid switch region (which we can denote functionally as being upstream of $C\\gamma 1$) and the $S\\alpha$ region. The intervening DNA segment between these two points is now `– Cγ1 –`. This segment is deleted to bring the $S\\alpha$ and $C\\alpha$ regions into proximity with the upstream V(D)J exon and promoter elements.\nThe final chromosomal DNA for this pathway, which allows for IgA expression, has also had the $C\\gamma 1$ gene excised. Therefore, for this subpopulation of cells that have completed the full switch to IgA, the fraction retaining $C\\gamma 1$ is also $0$.\n\nThe problem asks for the expected fraction of cells that retain the $C\\gamma 1$ exons *after they have completed switching to IgA*. Let $R$ be the event that $C\\gamma 1$ is retained. The expected fraction is the weighted average of the outcomes from the two pathways:\n$$ E[\\text{fraction}] = F_1 \\times (\\text{fraction retaining } C\\gamma 1 \\text{ in Pathway 1}) + F_2 \\times (\\text{fraction retaining } C\\gamma 1 \\text{ in Pathway 2}) $$\nAs we have determined, the fraction of cells retaining $C\\gamma 1$ in the final IgA-switched state is $0$ for both pathways.\n$$ E[\\text{fraction}] = (0.60) \\times (0) + (0.40) \\times (0) $$\n$$ E[\\text{fraction}] = 0 + 0 = 0 $$\nTherefore, in a system governed by deletional CSR, any switch to a downstream isotype (like IgA) necessitates the excision of all intervening constant region genes (like $C\\gamma 1$). The different pathways and their frequencies are irrelevant to the final state of the $C\\gamma 1$ gene on the chromosome. No cell that has successfully switched to produce IgA can retain the $C\\gamma 1$ gene on the same chromosome. The expected fraction is $0$. The question requires the answer as a decimal fraction.", "answer": "$$\n\\boxed{0.0}\n$$", "id": "2858655"}, {"introduction": "The successful repair of DNA double-strand breaks in CSR is not automatic; it is a highly regulated process involving a choice between competing pathways. This advanced exercise [@problem_id:2858689] delves into this molecular decision point, focusing on the antagonistic roles of the DNA repair proteins 53BP1 and BRCA1. By reasoning from their functions, you will predict how their absence alters the repair landscape, affecting DNA end resection, junctional characteristics, and overall CSR efficiency.", "problem": "A cohort of murine primary B lymphocytes is stimulated ex vivo with anti-CD40 and interleukin-4 to induce immunoglobulin class switch recombination (CSR) from $S\\mu$ to $S\\gamma 1$ (thereby generating immunoglobulin G1). You are given three otherwise isogenic groups: wild type, $53\\text{BP1}^{-/-}$, and $BRCA1^{-/-}$. Activation-induced cytidine deaminase (AID) deaminates cytosines within switch (S) regions to uracils, which are processed by base excision repair and mismatch repair to generate staggered double-strand breaks (DSBs). In the G1 phase of the cell cycle, CSR proceeds predominantly by classical non-homologous end joining (c-NHEJ), which is favored when DNA ends are protected from excessive $5^{\\prime}\\to 3^{\\prime}$ end resection. When resection is extended, microhomology-mediated end joining (MMEJ; also termed alternative end joining) becomes more competitive, typically yielding junctions with increased microhomology usage and often reducing productive CSR. The protein p53 binding protein 1 (53BP1) together with downstream effectors (for example, the RIF1–Shieldin axis) constrains end resection at DSBs, thereby promoting c-NHEJ during CSR, whereas breast cancer susceptibility protein 1 (BRCA1) antagonizes 53BP1-mediated end protection to enable end resection.\n\nUsing only these foundational facts about AID-induced DSB formation, phase-specific pathway choice, and the antagonistic control of end resection by 53BP1 versus BRCA1, predict, relative to wild type, the qualitative outcomes in $53\\text{BP1}^{-/-}$ versus $BRCA1^{-/-}$ B cells along the following three axes during $S\\mu$–$S\\gamma 1$ switching: (i) extent of end resection, (ii) microhomology usage at the $S\\mu$–$S\\gamma 1$ junctions, and (iii) overall switching efficiency (fraction of cells that successfully complete CSR to immunoglobulin G1). Select the option that most accurately captures all three features for both genotypes.\n\nA. $53\\text{BP1}^{-/-}$: increased end resection, increased microhomology at $S\\mu$–$S\\gamma 1$ junctions, reduced overall switching efficiency. $BRCA1^{-/-}$: decreased end resection, decreased microhomology at $S\\mu$–$S\\gamma 1$ junctions, near-normal to mildly reduced overall switching efficiency.\n\nB. $53\\text{BP1}^{-/-}$: decreased end resection, decreased microhomology at $S\\mu$–$S\\gamma 1$ junctions, increased overall switching efficiency. $BRCA1^{-/-}$: increased end resection, increased microhomology at $S\\mu$–$S\\gamma 1$ junctions, reduced overall switching efficiency.\n\nC. $53\\text{BP1}^{-/-}$ and $BRCA1^{-/-}$: both show increased end resection and increased microhomology at $S\\mu$–$S\\gamma 1$ junctions, with similarly reduced overall switching efficiency.\n\nD. $53\\text{BP1}^{-/-}$: increased end resection and increased microhomology at $S\\mu$–$S\\gamma 1$ junctions, increased overall switching efficiency. $BRCA1^{-/-}$: decreased end resection and decreased microhomology at $S\\mu$–$S\\gamma 1$ junctions, substantially increased overall switching efficiency.", "solution": "The problem statement is subjected to validation.\n\n**Step 1: Extract Givens**\n-   A cohort of murine primary B lymphocytes is stimulated ex vivo with anti-CD40 and interleukin-4.\n-   The stimulation induces immunoglobulin class switch recombination (CSR) from $S\\mu$ to $S\\gamma 1$, generating immunoglobulin G1 (IgG1).\n-   Three isogenic groups exist: wild type (WT), $53\\text{BP1}^{-/-}$, and $BRCA1^{-/-}$.\n-   Activation-induced cytidine deaminase (AID) creates uracils from cytosines in switch (S) regions.\n-   Base excision repair and mismatch repair process uracils to generate staggered double-strand breaks (DSBs).\n-   In the G1 phase of the cell cycle, CSR predominantly uses classical non-homologous end joining (c-NHEJ).\n-   c-NHEJ is favored when DNA ends are protected from excessive $5^{\\prime}\\to 3^{\\prime}$ end resection.\n-   Extended resection makes microhomology-mediated end joining (MMEJ) more competitive.\n-   MMEJ leads to junctions with increased microhomology and often reduces productive CSR efficiency.\n-   p53 binding protein 1 (53BP1) constrains end resection at DSBs, promoting c-NHEJ.\n-   Breast cancer susceptibility protein 1 (BRCA1) antagonizes 53BP1-mediated end protection to enable end resection.\n\n**Step 2: Validate Using Extracted Givens**\nThe problem is scientifically sound, grounded in established principles of molecular immunology and DNA repair. The roles of AID, CSR, c-NHEJ, MMEJ, 53BP1, and BRCA1 are described in accordance with current scientific understanding. The problem is well-posed, providing a set of clear premises and asking for logical deductions about predictable outcomes in knockout models. The language is objective and technical. The setup is self-contained and does not contain contradictions. The experimental context (ex vivo stimulation of B cells) is realistic.\n\n**Step 3: Verdict and Action**\nThe problem is valid. A solution will be derived based on the provided premises.\n\n**Derivation of Solution**\n\nThe problem requires a qualitative prediction of three parameters—(i) extent of end resection, (ii) microhomology usage, and (iii) overall switching efficiency—for $53\\text{BP1}^{-/-}$ and $BRCA1^{-/-}$ B cells relative to wild type. The logical derivation proceeds from the given functions of the proteins 53BP1 and BRCA1.\n\n**Fundamental Principles from Problem Statement:**\n1.  **End Resection Control:** 53BP1 *constrains* resection, while BRCA1 *enables* (promotes) resection by antagonizing 53BP1.\n2.  **Pathway Choice:** Limited resection favors c-NHEJ (the main CSR pathway). Extended resection favors MMEJ.\n3.  **Consequences of Pathway Choice:** MMEJ is associated with increased microhomology at repair junctions and reduced overall CSR efficiency compared to c-NHEJ.\n\n**Analysis of the Wild Type (WT) Baseline:**\nIn WT cells, a functional balance exists between the pro-resection activity of BRCA1 and the anti-resection activity of 53BP1. This balance fine-tunes the level of DSB end resection in the G1 phase to favor the efficient c-NHEJ pathway for CSR, establishing the baseline for resection, microhomology, and switching efficiency.\n\n**Analysis of the $53\\text{BP1}^{-/-}$ Genotype:**\n1.  **End Resection:** The problem states that 53BP1 *constrains* end resection. In the absence of this constraint ($53\\text{BP1}^{-/-}$), the pro-resection activity of BRCA1 is unopposed. Consequently, the extent of $5^{\\prime}\\to 3^{\\prime}$ end resection will be **increased** relative to WT.\n2.  **Microhomology Usage:** The problem states that extended resection makes MMEJ more competitive, and MMEJ yields junctions with increased microhomology. Since end resection is increased in $53\\text{BP1}^{-/-}$ cells, repair will shift towards MMEJ. Therefore, microhomology usage at $S\\mu$–$S\\gamma 1$ junctions will be **increased**.\n3.  **Overall Switching Efficiency:** The problem states that MMEJ reduces productive CSR and that 53BP1 promotes c-NHEJ, the predominant pathway for CSR. In the absence of 53BP1, the efficient c-NHEJ pathway is impaired, and the cell relies more on the less efficient MMEJ pathway. This leads to a **reduced** overall switching efficiency.\n\n**Summary for $53\\text{BP1}^{-/-}$:** Increased end resection, increased microhomology, reduced efficiency.\n\n**Analysis of the $BRCA1^{-/-}$ Genotype:**\n1.  **End Resection:** The problem states that BRCA1 *antagonizes* 53BP1 to *enable* end resection. In the absence of this pro-resection protein ($BRCA1^{-/-}$), the anti-resection activity of 53BP1 is unopposed. Therefore, end resection will be more severely constrained, leading to **decreased** end resection relative to WT.\n2.  **Microhomology Usage:** The problem states that c-NHEJ is favored when ends are protected from resection. With decreased resection in $BRCA1^{-/-}$ cells, the conditions for c-NHEJ are enhanced, and the alternative MMEJ pathway is suppressed. As MMEJ is the source of increased microhomology, microhomology usage at $S\\mu$–$S\\gamma 1$ junctions will be **decreased**.\n3.  **Overall Switching Efficiency:** With end resection decreased, pathway choice is strongly skewed towards c-NHEJ, the main pathway for CSR. However, the WT state represents an optimized balance. The complete loss of BRCA1, which \"enables\" resection, may impair the overall process even if it favors the \"correct\" pathway choice, for instance, by preventing necessary cleanup of DSB ends. A biological system removed from its homeostatic balance rarely performs better. Thus, a \"substantially increased\" efficiency is highly unlikely. A more logical outcome is that efficiency is either largely unaffected or slightly compromised. Therefore, a **near-normal to mildly reduced** overall switching efficiency is the most reasonable prediction.\n\n**Summary for $BRCA1^{-/-}$:** Decreased end resection, decreased microhomology, near-normal to mildly reduced efficiency.\n\n**Evaluation of Options**\n\n**A. $53\\text{BP1}^{-/-}$: increased end resection, increased microhomology at $S\\mu$–$S\\gamma 1$ junctions, reduced overall switching efficiency. $BRCA1^{-/-}$: decreased end resection, decreased microhomology at $S\\mu$–$S\\gamma 1$ junctions, near-normal to mildly reduced overall switching efficiency.**\nThis option perfectly matches the derived predictions for both genotypes based on the principles provided in the problem statement.\n**Verdict: Correct.**\n\n**B. $53\\text{BP1}^{-/-}$: decreased end resection, decreased microhomology at $S\\mu$–$S\\gamma 1$ junctions, increased overall switching efficiency. $BRCA1^{-/-}$: increased end resection, increased microhomology at $S\\mu$–$S\\gamma 1$ junctions, reduced overall switching efficiency.**\nThis option incorrectly states the opposite phenotype for each genotype. For example, it claims decreased resection in $53\\text{BP1}^{-/-}$ cells, which contradicts the stated function of 53BP1 as a resection antagonist. The phenotypes for the two knockouts appear to be swapped.\n**Verdict: Incorrect.**\n\n**C. $53\\text{BP1}^{-/-}$ and $BRCA1^{-/-}$: both show increased end resection and increased microhomology at $S\\mu$–$S\\gamma 1$ junctions, with similarly reduced overall switching efficiency.**\nThis option claims that the two knockouts have similar phenotypes. This contradicts the premise that 53BP1 and BRCA1 have antagonistic functions regarding end resection. Their absence should lead to opposite, not similar, effects on resection and its downstream consequences.\n**Verdict: Incorrect.**\n\n**D. $53\\text{BP1}^{-/-}$: increased end resection and increased microhomology at $S\\mu$–$S\\gamma 1$ junctions, increased overall switching efficiency. $BRCA1^{-/-}$: decreased end resection and decreased microhomology at $S\\mu$–$S\\gamma 1$ junctions, substantially increased overall switching efficiency.**\nThis option incorrectly predicts an increased overall switching efficiency for the $53\\text{BP1}^{-/-}$ genotype, which contradicts the premise that the resulting shift to MMEJ reduces productive CSR. It also predicts a substantially increased efficiency for the $BRCA1^{-/-}$ genotype, which is biologically implausible, as knocking out a key regulator of a finely balanced system is unlikely to improve its efficiency.\n**Verdict: Incorrect.**", "answer": "$$\\boxed{A}$$", "id": "2858689"}]}